gil-c-shutterstock-com-johnson-johnson-
Gil C / Shutterstock.com
16 May 2019Big Pharma

Federal Circuit rules against J&J in Zytiga dispute

The US Court of Appeals for the Federal Circuit delivered a  blow to Johnson & Johnson (J&J) on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga (abiraterone acetate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
29 October 2018   Johnson & Johnson has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).
Americas
18 January 2018   The Patent Trial and Appeal Board has invalidated a Johnson & Johnson patent covering its prostate cancer drug Zytiga (abiraterone acetate).
Big Pharma
10 October 2019   Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.

More on this story

Americas
29 October 2018   Johnson & Johnson has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).
Americas
18 January 2018   The Patent Trial and Appeal Board has invalidated a Johnson & Johnson patent covering its prostate cancer drug Zytiga (abiraterone acetate).
Big Pharma
10 October 2019   Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.

More on this story

Americas
29 October 2018   Johnson & Johnson has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).
Americas
18 January 2018   The Patent Trial and Appeal Board has invalidated a Johnson & Johnson patent covering its prostate cancer drug Zytiga (abiraterone acetate).
Big Pharma
10 October 2019   Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.